A new rating scale to evaluate the potential benefit of therapeutic drug monitoring

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: author
Serval ID
serval:BIB_3D37BCBBB4E9
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
A new rating scale to evaluate the potential benefit of therapeutic drug monitoring
Title of the conference
12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology
Author(s)
Bruenen S., Vincent P.D., Baumann P., Hiemke C., Havemann-Reinecke U.
Address
Stuttgart, Germany, October 2-6, 2011
ISBN
0163-4356
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
33
Series
Therapeutic Drug Monitoring
Pages
499-500
Language
english
Notes
Publication type : Meeting Abstract
Abstract
Aims: Therapeutic Drug Monitoring (TDM) is an established tool to optimize thepharmacotherapy with immunosupressants, antibiotics, antiretroviral agents, anticonvulsantsand psychotropic drugs. The TDM expert group of the Association ofNeuropsychopharmacolgy and Pharmacopsychiatry recommended clinical guidelinesfor TDM of psychotropic drugs in 2004 and in 2011. They allocate 4 levelsof recommendation based on studies reporting plasma concentrations and clinicaloutcomes. To evaluate the additional benefit for drugs without direct evidence forTDM and to verify the recommendation levels of the expert group the authorsbuilt a new rating scale. Methods: This rating scale included 28 items and wasdivided in 5 categories: Efficacy, toxicity, pharmacokinetics, patient characteristicsand cost effectiveness. A literature search was performed for 10 antidepressants,10 antipsychotics, 8 drugs used in the treatment of substance related disordersand lithium, thereafter, a comparison with the assessment of the TDMexpert group was carried out. Results: The antidepressants as well as the antipsychoticsshowed a high and significant correlation with the recommendations inthe consensus guidelines. However, meanderings could be detected for the drugsused in the therapy of substance related disorders, for which TDM is mostly notestablished yet. The result of the antidepressants and antipsychotics permits aclassification of the reachable points; upper 13 - TDM strongly recommended10 to 13 - TDM recommended, 8 to 10 - TDM useful and below 8 - TDMpotentially useful. Conclusion: These results suggest this rating scale is sensitiveto detect the appropriateness of TDM for drug treatment. For those drugs TDM isnot established a more objective estimation is possible, thus the scoring helps tofocus on the most likely drugs to require TDM.
Keywords
therapeutic drug monitoring, affective disorder, rating scale, schizophrenia, substance related disorder,
Web of science
Create date
04/10/2011 14:57
Last modification date
20/08/2019 14:33
Usage data